Cyclosporin analogues and uses in hepatitis b therapies
Cyclosporin analogues with enhanced solubility and reduced toxicity address the limitations of Cyclosporin A, offering effective HBV treatment with improved bioavailability and safety.
WO2026119137A1 Publication Date: 2026-06-11FARSIGHT MEDICAL TECH (SHANGHAI) CO LTD
8 Cites 0 Cited by
Patent Information
- Application Number
- PCT/CN2025/139382
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-12-03
- Filing Date
- 2025-12-02
- Publication Date
- 2026-06-11
AI Technical Summary
Technical Problem
Cyclosporin A, while effective against HBV, is highly potent and toxic, causing severe side effects and has low water solubility, limiting its bioavailability and absorption.
Method used
Development of cyclosporin analogues with improved pharmacokinetic properties and targeted HBV infection mechanisms, including enhanced water solubility through the creation of pharmaceutically acceptable salts, such as malate salts, to enhance bioavailability and reduce toxicity.
Benefits of technology
The cyclosporin analogues provide effective prevention and treatment of HBV infection with reduced toxicity and improved solubility, facilitating better oral bioavailability and formulation for parenteral administration.
✦ Generated by Eureka AI based on patent content.
Abstract
The compounds or pharmaceutically acceptable salts thereof as defined by Formulas 1-6 and uses thereof for the prevention or treatment of diseases or conditions such a hepatitis B virus infection or diseases or conditions arising as a result of a hepatitis B virus infection.
Need to check novelty before this filing date? Find Prior Art